secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001558370-23-019023
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu Q1 FY2024: Adjusted EBITDA $2.2M (+32% YoY), ADHD revenue up 31%
---------------------------------------------------------------------

- Net revenue $22.1M (down 20% YoY) due to Consumer Health wind-down; Rx segment $17.8M.
- ADHD net revenue $15.1M, up 31% YoY; pediatric revenue $2.6M impacted by payor changes.
- Net loss $8.1M ($1.48/sh) vs $0.7M loss last year; includes $5.9M loss on derivative warrant liabilities.
- Adjusted EBITDA $2.2M vs $1.7M YoY; Rx segment Adjusted EBITDA $2.4M.
- Cash $20.0M at Sept 30, 2023; FDA approvals for manufacturing site transfers for Adzenys and Cotempla.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000155837023019023/0001558370-23-019023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000155837023019023/aytu-20231114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-019023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer